According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “
A number of other equities research analysts also recently commented on IGXT. HC Wainwright reiterated a “buy” rating and set a $1.00 price objective on shares of IntelGenx Technologies in a research report on Monday. Maxim Group reiterated a “buy” rating and set a $1.50 price objective on shares of IntelGenx Technologies in a research report on Friday, August 9th.
IntelGenx Technologies (OTCMKTS:IGXT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). IntelGenx Technologies had a negative net margin of 541.77% and a negative return on equity of 175.02%. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.90 million. As a group, research analysts forecast that IntelGenx Technologies will post -0.07 earnings per share for the current fiscal year.
IntelGenx Technologies Company Profile
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Further Reading: Diversification in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.